List of works - Hojabr Kakavand

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

scientific article

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage

scientific article published on 5 July 2013

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making

scientific article

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

article

Comprehensive Characterization of Cancer Driver Genes and Mutations

article

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

scientific article published in April 2014

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

scientific article

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

scientific article published on 16 May 2017

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

scientific article

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

scientific article published on 3 April 2015

How anti-PD1 treatments are changing the management of melanoma.

scientific article published in November 2014

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients

scientific article published on 3 July 2013

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma

scientific article

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

scientific article published on 23 August 2013

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

scientific article published on 4 August 2017

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

scientific article

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

scientific article

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

article

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

scientific article

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists

scientific article published on 20 January 2016

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

scientific article published on 25 September 2015

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

scientific article published on 29 October 2015

Whole-genome landscapes of major melanoma subtypes.

scientific article published on 3 May 2017

List of works by Hojabr Kakavand

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Comprehensive Characterization of Cancer Driver Genes and Mutations

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

How anti-PD1 treatments are changing the management of melanoma.

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Whole-genome landscapes of major melanoma subtypes.